ROYALTIES TO LICENSOR Clause Samples

ROYALTIES TO LICENSOR. 5.1 Licensee shall pay to Licensor, as an advance royalty payment, the amount of $50,000. Licensee shall pay the advance royalty payment either by immediately available funds within five (5) days following the Effective Date or by opening an irrevocable standby letter of credit in favor of Licensor on the Effective Date, with a bank reasonably satisfactory to Licensor and that maintains a confirmation relationship with Licensor's bank, in the amount of $50,000, payable within five (5) days. The advance royalty payment shall be non- refundable and shall be credited against the Minimum Royalty Fee as set forth herein so that no Royalty Fees as defined herein shall be payable by Licensee until Licensee's advance royalty credit is reduced to zero. (a) Licensee shall also pay to Licensor a fee ("Royalty Fee") equal to the percentage rate for the particular category of Goods on EXHIBIT E hereto multiplied by the amount over ex-factory cost of the Goods directly or indirectly sold by Licensee for each particular category of Goods. The term "ex- factory cost" shall mean the manufacturer's actual invoiced price prior to any discounts, rebates or allowances. Licensee shall be required to pay a Minimum Royalty Fee for the Term of $200,000, which is calculated by taking the product of the minimum gross sales required for the Term as set forth herein, and four percent (4%). If the Royalty Fees paid to Licensor for the Term do not equal or exceed the Minimum Royalty Fee, Licensee shall promptly pay to Licensor the difference between the Royalty Fees actually paid and the Minimum Royalty Fee.
View SourceView Similar (2)
ROYALTIES TO LICENSOR. Royalties to Licensor will be due and payable according to the following terms. (i) Licensee will pay Licensor a royalty of [ * ]% of Net Profits of Licensed Product as long as there is at least one unexpired Valid Claim in a Licensed Patent, an Improvement, Joint Improvement or Licensee Improvement and the Valid Claim covers (I) the manufacturing or sale of HE3286, (II) formulations or any Dosage Form that contains HE3286 or (III) any method that uses HE3286 in one or more treatments in the Field of Use. Licensee will pay Licensor a royalty of [ * ]% of Net Profits of Licensed Product that uses a product improvement that is covered by a valid claim in a Licensee Improvement, wherein the product improvement is mutually agreed in writing to be superior or otherwise significantly improve the bioavailability or another useful property of HE3286 and the product improvement is used or present in a Licensed Product. (ii) Net Profit (iii) Licensee will pay Licensor a royalty of [ * ]% of Net Profits of Licensed Product that is covered by an issued and valid claim in a Joint Improvement or Licensee Improvement and there is no unexpired Valid Claim remaining in or arising from any Licensed Patent or Improvement, where such Valid Claim covers (I) the manufacturing or sale of HE3286, (II) formulations or any Dosage Form that contains HE3286 or (III) methods that use HE3286 in one or more treatments in the Field of Use. (iv) If Licensee enters into one or more sublicense agreements before the end of the last phase II clinical trial for each or any clinical indication in the Field of Use, Licensee will pay [ * ]% of all royalties on all Net Profits that Licensee is paid under each sublicense. If Licensee enters into one or more sublicense agreements before the end of the last phase III clinical trial for each or any clinical indication in the Field of Use, Licensee will pay [ * ]% of all royalties on all Net Profits that Licensee is paid under each sublicense. If Licensee enters into one or more sublicense agreements after the end of the last phase III clinical trial for each or any clinical indication in the Field of Use but before the first royalty generating sale in China or Hong Kong, Licensee will pay [ * ]% of all royalties on all Net Profits that Licensee is paid under each sublicense. As used herein, the end of any clinical trial, e.g., phase II clinical trial or phase III clinical trial means that dosing of patients has been completed and the results have been...
View SourceView Similar (2)
ROYALTIES TO LICENSOR. (a) Licensee shall pay to Licensor for each Licensed Product licensed to a Redistributor or a Customer a royalty equal to the Specified Royalty Percentage of all revenues received (without deduction for value added tax, if any, but excluding any revenues for maintenance and support or upgrade services, which revenues are covered in paragraph (b) below) by Licensee under the Redistributor Agreement or Sublicense applicable to such Licensed Product. (b) Licensee shall pay to Licensor for maintenance and support and upgrade services provided under the applicable Sublicense or other written maintenance and support agreement with or approved by Licensee for each of the Licensed Products a royalty equal to the Specified Royalty Percentage of all revenues received (without deduction for value added tax, if any) by Licensee from a Redistributor or Customer relating to maintenance and support services or services for Upgrades or upgrades of systems for such Licensed Products.
View Source
ROYALTIES TO LICENSOR. 5.1 Royalties due to Licensor by Licensee for the sale of Goods shall be calculated based upon the classification of the Goods into two product categories: (1) voice activated products and (2) core products. Voice activated products shall be all Goods which are activated utilizing a voice recognition feature and do not require manual activation, and core products shall be all Goods which are not voice activated products. 5.2 Voice activated product royalties shall be calculated based upon a percentage of Licensee's Gross Profits as set forth in Exhibit E. For purposes of calculating such royalties "Gross Profits" shall mean the product Sales Price less the product's Landed Cost, as these terms are defined in Sections 1.6 and 1.8, respectively. Payment of royalties on voice activated products are due within ten (10) calendar days after the end of each month and shall be accompanied by a certified monthly royalty statement in the form attached as Schedule 5.
View Source
ROYALTIES TO LICENSOR. 5.1 [redacted] (a) Licensee shall also pay to Licensor as royalties ("Royalties") a sum equal to the royalty rate for the particular category of Goods on Exhibit E hereto multiplied by the "Gross Sales Value" of the Goods sold by Licensee for
View Source
ROYALTIES TO LICENSOR. Ventrus shall pay to Licensor the following royalties on Annual Net Sales of each Ventrus Product and Ventrus Therapy on a worldwide basis provided such Ventrus Product or Ventrus Therapy is Covered by a Valid Claim of a Licensor Patent: Annual Net Sales of applicable Product or Therapy on sales of less than $[*] million [*]% of such Net Sales Annual Net Sales of applicable Product or Therapy on sales of $[*] million or more [*]% of such Net Sales If Annual Net Sales of applicable Product or Therapy are between $[*] million and less than $[*] million $[*] million one-time payment with respect the applicable Product or Therapy (in addition to any other of Ventrus’s royalty obligations or payments) If Annual Net Sales Of applicable Product or Therapy are $[*] million or more $[*] million one-time payment with respect the applicable Product or Therapy (in addition to any other Ventrus’s royalty obligations or payments) [*] Confidential treatment requested; certain information omitted and filed separately with the SEC.
View Source

Related to ROYALTIES TO LICENSOR

  • Licensee “Licensee” means the individual or company that has entered into an Agreement with the Embassy. “Offer” means a response to a solicitation that, if accepted, would bind the offeror to perform the resultant Agreement.

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner. 4.2 The Parties shall negotiate with each other to enter into specific technology license contracts to expressly specify the detail matters such as the technology to be licensed, the method to license the technology, license fees and payment.